Blue Marlin Therapeutics, Inc.

CHARLOTTESVILLE, VA · Founded 2025 · CIK 0002092364 · Biotech · Private

Programmable in vivo immune-cell therapies using engineered cells that can be controlled post-administration

bluemarlin.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$100K
1 Form D · Oct 2025
12 months since last filing
Contracts
—
No federal contracts on record
Patents
9
0 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$100,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2656nVector, Inc.—$125K
2657Sustained Therapeutics Inc.—$100K
2658GALIBRA NEUROSCIENCE, INC.—$100K
2659Blue Marlin Therapeutics, Inc.—$100K
2660CINDER BIOLOGICAL, INC.—$100K
2661Nano Pharmasolutions Inc.—$75K
2662Normunity——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Paul ManningExecutive Officer
  • Sean StalfortExecutive Officer

Patents

USPTO · 0 granted of 9
  • Mobile Genetic Elements From Eptesicus Fuscusapplication
  • Mobile Elements And Chimeric Constructs Thereofapplication
  • Transposition-based Therapiesapplication
  • Compositions And Methods For Treatment Of Inherited Macular Degenerationapplication
  • Compositions And Methods For Treatment Of Cystic Fibrosisapplication
  • Myotis Lucifugus Transposase Engineeringapplication
  • Compositions And Methods Of Using Gene Coding For Treating Ocular Diseaseapplication
  • Myotis Lucifugus Transposase Engineeringapplication
  • Mobile Genetic Elements From Myotis Myotisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.